The Ketamine Trial for Acute Suicidality (KETA): Study Protocol of a Double‐Blind Randomized Placebo‐Controlled Superiority Trial on Intranasal Racemic Ketamine Compared to the Active Placebo Intranasal Midazolam as Treatment for Acute Suicidality
International Journal of Methods in Psychiatric Research · 2025
DOI: 10.1002/mpr.70044 ↗At a glance
Studienprotokoll in International Journal of Methods in Psychiatric Research, 2025. Written by Jurriaan F M Strous and 5 co-authors. Institution: Department of Psychiatry, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. Major MEDLINE topics: Ketamine, Midazolam, Suicidal Ideation, Outcome Assessment, Health Care. 93 references. The full text is freely available (open access, CC BY 4.0). Funded by: ZonMw.
Abstract (original language)
Background
Suicidality is a transdiagnostic entity in patients with and without psychiatric disorders. Ketamine is a novel treatment for treatment‐resistant depression with favorable effects on related suicidality in this population. Little is known about the effects of ketamine on suicidality as a distinct phenomenon.
Objective
To assess whether a dose of 75 mg intranasal (IN) ketamine reduces acute suicidality relative to a 4 mg intranasal dose of the active placebo midazolam, 180 min after administration. Methods/design A double‐blind randomized placebo‐controlled trial ( N = 100) will assess the efficacy of fixed‐dose IN racemic ketamine in patients presenting with acute suicidality, regardless of psychiatric diagnosis. Participants receive a single IN dose of either racemic ketamine (75 mg) or midazolam (4 mg) along with treatment as usual. The primary outcome is the reduction in suicidal ideation as measured by the Beck Scale for Suicide Ideation (BSSI) at 180 min. Secondary outcomes include depression severity with the Montgomery Åsberg Depression Rating Scale (MADRS) and tolerability with the Systematic Assessment for Treatment Emerging Effects (SAFTEE) as well as blood‐based and neuroimaging markers.
Discussion
This study design considers key aspects such as patient selection, ketamine formulation, clinical management, and the follow‐up time points. Potential risks, limitations, and future considerations are additionally discussed. Trial Registration EudraCT 2020‐002905‐24, registered 6 October 2021
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Psychiatry, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
- Lentis Mental Health Care, Groningen, the Netherlands.
ORCID profiles: Jurriaan F M Strous, Robert A Schoevers
Funding
- ZonMw
Cite
APA
Strous, J. F. M., Roelandt, G. H. J., van Dalfsen, J. H., Kamphuis, J., Marijnissen, R. M., & Schoevers, R. A. (2025). The Ketamine Trial for Acute Suicidality (KETA): Study Protocol of a Double‐Blind Randomized Placebo‐Controlled Superiority Trial on Intranasal Racemic Ketamine Compared to the Active Placebo Intranasal Midazolam as Treatment for Acute Suicidality. International Journal of Methods in Psychiatric Research. https://doi.org/10.1002/mpr.70044
Vancouver
Strous JFM, Roelandt GHJ, van Dalfsen JH, Kamphuis J, Marijnissen RM, Schoevers RA. The Ketamine Trial for Acute Suicidality (KETA): Study Protocol of a Double‐Blind Randomized Placebo‐Controlled Superiority Trial on Intranasal Racemic Ketamine Compared to the Active Placebo Intranasal Midazolam as Treatment for Acute Suicidality. International Journal of Methods in Psychiatric Research. 2025. doi:10.1002/mpr.70044
BibTeX
@article{Strous2025,
author = {Strous, Jurriaan F M and Roelandt, Gijs H J and van Dalfsen, Jens H and Kamphuis, Jeanine and Marijnissen, Radboud M and Schoevers, Robert A},
title = {The Ketamine Trial for Acute Suicidality (KETA): Study Protocol of a Double‐Blind Randomized Placebo‐Controlled Superiority Trial on Intranasal Racemic Ketamine Compared to the Active Placebo Intranasal Midazolam as Treatment for Acute Suicidality},
journal = {International Journal of Methods in Psychiatric Research},
year = {2025},
doi = {10.1002/mpr.70044}
}
EUVIMED